SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Study leads

Jens Hillengass, MD
Principal Investigator
Roswell Park

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Phoenix, United States · Derby, United States

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Ames, United States · Ames, United States

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Extramedullary Disease in Multiple Myeloma · Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Buffalo, United States

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Coral Gables, United States · Deerfield Beach, United States